IL295408A - Bacteriophage compositions for treating staphylococcus infection - Google Patents

Bacteriophage compositions for treating staphylococcus infection

Info

Publication number
IL295408A
IL295408A IL295408A IL29540822A IL295408A IL 295408 A IL295408 A IL 295408A IL 295408 A IL295408 A IL 295408A IL 29540822 A IL29540822 A IL 29540822A IL 295408 A IL295408 A IL 295408A
Authority
IL
Israel
Prior art keywords
bacteriophage
seq
polynucleotide sequence
composition
identity
Prior art date
Application number
IL295408A
Other languages
English (en)
Hebrew (he)
Original Assignee
Armata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armata Pharmaceuticals Inc filed Critical Armata Pharmaceuticals Inc
Publication of IL295408A publication Critical patent/IL295408A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL295408A 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection IL295408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978006P 2020-02-18 2020-02-18
PCT/US2021/018623 WO2021168147A1 (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection

Publications (1)

Publication Number Publication Date
IL295408A true IL295408A (en) 2022-10-01

Family

ID=77272316

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295408A IL295408A (en) 2020-02-18 2021-02-18 Bacteriophage compositions for treating staphylococcus infection

Country Status (8)

Country Link
US (4) US20210252083A1 (https=)
EP (1) EP4106782A4 (https=)
JP (1) JP2023513934A (https=)
CN (1) CN115397447A (https=)
AU (1) AU2021224912A1 (https=)
CA (1) CA3171467A1 (https=)
IL (1) IL295408A (https=)
WO (1) WO2021168147A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872519B1 (en) * 1999-04-27 2005-03-29 Mirus Bio Corporation In vitro process for selecting phage resistant to blood inactivation
US11214773B2 (en) * 2015-09-24 2022-01-04 San Diego State University (Sdsu) Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
CN110719784A (zh) * 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
EP3372085A1 (en) * 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
CN112218659A (zh) * 2018-01-02 2021-01-12 阿玛塔制药股份有限公司 用于治疗葡萄球菌感染的治疗性噬菌体组合物

Also Published As

Publication number Publication date
EP4106782A1 (en) 2022-12-28
WO2021168147A1 (en) 2021-08-26
US20240189373A1 (en) 2024-06-13
AU2021224912A1 (en) 2022-09-01
US20230092021A1 (en) 2023-03-23
US20260041723A1 (en) 2026-02-12
JP2023513934A (ja) 2023-04-04
CN115397447A (zh) 2022-11-25
US20210252083A1 (en) 2021-08-19
CA3171467A1 (en) 2021-08-26
EP4106782A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
Pirnay et al. Recent progress toward the implementation of phage therapy in Western medicine
Wang et al. Novel therapeutic interventions towards improved management of septic arthritis
Mukhopadhyay et al. Sequential treatment effects on phage–antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii
RU2234940C2 (ru) Способ лечения стафилококковых инфекций у млекопитающего (варианты)
WO2011014693A2 (en) Bacteriophages expressing amyloid peptides and uses thereof
US20120328576A1 (en) Defined dose therapeutic phage
JP7449967B2 (ja) 療法バクテリオファージ組成物
AU2004258731A1 (en) Bacteriophage-containing therapeutic agents
JP2023182703A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染症を処置するための治療的バクテリオファージ組成物
IL295167A (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
IL296741A (en) Bacteriophage compositions for treating pseudomonas infection
US20190142881A1 (en) Bacteriophage compositions and uses thereof
RU2729934C2 (ru) Антибактериальная композиция и способ лечения стафилококковых инфекций антибактериальной композицией
Lin et al. Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii
IL295408A (en) Bacteriophage compositions for treating staphylococcus infection
JP7289538B2 (ja) 新規バクテリオファージおよび細菌性眼内炎治療剤
Megha et al. Bacteriophage therapy: Unleashing the potential of bacteriophages in modern medicine
Liu et al. RETRACTED: Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin
US20220160842A1 (en) Method of treating infective endocarditis
Bhadoriya et al. A review on re-emerging bacteriophage therapy in the era of XDR
Sakib et al. The combination of bacteriophage therapy and antibiotic therapy
Jung et al. Bacteriophage-liposomes complex, a bi-therapy system to target Streptococcus pneumonia and biofilm: A research protocol
CN120643575A (zh) ENOBlock在制备治疗脓毒症的药物中的应用
Wu Development of Antibiotic-Encapsulated Escherichia coli Outer Membrane Vesicles as Novel Antibiotic Agent to Overcome Resistance Mechanism
AL-Ishaq et al. Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens. Viruses 2021, 13, 51